申请人:Tatani Kazuya
公开号:US20120129890A1
公开(公告)日:2012-05-24
A compound (I) of the present invention, which has an EP
1
receptor antagonism:
[wherein A represents a benzene ring or the like; Y
1
represents a C
1-6
alkylene group; Y
2
represents a single bond or the like; R
1
represents a hydrogen atom, a C
1-6
alkyl group or the like; R
2
represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic ring which may have a substituent, a 6-membered aromatic heterocyclic ring which may have a substituent or the like; R
3
represents a halogen atom, a C
1-6
alkoxy group or the like; R
4
represents a hydrogen atom or the like; and R
5
represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.
本发明提供了一种具有EP1受体拮抗作用的化合物(I)[其中A代表苯环或类似结构;Y1代表C1-6烷基亚基;Y2代表单键或类似结构;R1代表氢原子、C1-6烷基团或类似结构;R2代表可能含有取代基的苯基、可能含有取代基的5元芳香杂环、可能含有取代基的6元芳香杂环或类似结构;R3代表卤素原子、C1-6烷氧基团或类似结构;R4代表氢原子或类似结构;R5代表氢原子或类似结构]或其药物可接受的盐。此外,本发明的化合物(I)可用作治疗或预防LUTS的药物,特别是OAB的各种症状。